Business Description
Ligand Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US53220K5048
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 29.93 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.09 | |||||
Interest Coverage | 5.18 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 14.48 | |||||
Beneish M-Score | -2.15 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.7 | |||||
3-Year EBITDA Growth Rate | 18.7 | |||||
3-Year EPS without NRI Growth Rate | 22.2 | |||||
3-Year Book Growth Rate | -3.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 105.03 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.01 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 69.21 | |||||
9-Day RSI | 66.42 | |||||
14-Day RSI | 62.65 | |||||
6-1 Month Momentum % | 40 | |||||
12-1 Month Momentum % | 86.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.82 | |||||
Quick Ratio | 16.04 | |||||
Cash Ratio | 12.22 | |||||
Days Inventory | 749.64 | |||||
Days Sales Outstanding | 89.05 | |||||
Days Payable | 121.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | 3.53 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.82 | |||||
Operating Margin % | 5.98 | |||||
Net Margin % | 31.57 | |||||
FCF Margin % | -5.79 | |||||
ROE % | 5.83 | |||||
ROA % | 5.15 | |||||
ROIC % | 1.09 | |||||
3-Year ROIIC % | 28.04 | |||||
ROC (Joel Greenblatt) % | 76.1 | |||||
ROCE % | 6.82 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 46.27 | |||||
Forward PE Ratio | 17.59 | |||||
PE Ratio without NRI | 22.89 | |||||
Shiller PE Ratio | 16.47 | |||||
Price-to-Owner-Earnings | 61.05 | |||||
PS Ratio | 14.26 | |||||
PB Ratio | 2.5 | |||||
Price-to-Tangible-Book | 5 | |||||
Price-to-Operating-Cash-Flow | 40.05 | |||||
EV-to-EBIT | 31.78 | |||||
EV-to-Forward-EBIT | 23.14 | |||||
EV-to-EBITDA | 19.41 | |||||
EV-to-Forward-EBITDA | 23.14 | |||||
EV-to-Revenue | 12.99 | |||||
EV-to-Forward-Revenue | 9.69 | |||||
EV-to-FCF | -212.38 | |||||
Price-to-Projected-FCF | 1.62 | |||||
Price-to-Median-PS-Value | 1.41 | |||||
Price-to-Graham-Number | 2.26 | |||||
Price-to-Net-Current-Asset-Value | 8.76 | |||||
Price-to-Net-Cash | 14.24 | |||||
Earnings Yield (Greenblatt) % | 3.15 | |||||
FCF Yield % | -0.42 | |||||
Forward Rate of Return (Yacktman) % | -1.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ligand Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 123.648 | ||
EPS (TTM) (€) | 2.086 | ||
Beta | 1.28 | ||
Volatility % | 47.2 | ||
14-Day RSI | 62.65 | ||
14-Day ATR (€) | 1.650786 | ||
20-Day SMA (€) | 92.9 | ||
12-1 Month Momentum % | 86.48 | ||
52-Week Range (€) | 47 - 103 | ||
Shares Outstanding (Mil) | 18.27 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ligand Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ligand Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ligand Pharmaceuticals Inc Frequently Asked Questions
What is Ligand Pharmaceuticals Inc(FRA:LGDN)'s stock price today?
When is next earnings date of Ligand Pharmaceuticals Inc(FRA:LGDN)?
Does Ligand Pharmaceuticals Inc(FRA:LGDN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |